Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A composition of biomarkers for distinguishing subtypes of breast cancer

A breast cancer, diagnostic composition technology, applied in the direction of material separation, analysis materials, instruments, etc., can solve the problem of differentiating breast cancer molecular type and so on

Active Publication Date: 2017-10-13
CHINA PHARM UNIV
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No one has used plasma metabolite levels to differentiate breast cancer molecular subtypes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A composition of biomarkers for distinguishing subtypes of breast cancer
  • A composition of biomarkers for distinguishing subtypes of breast cancer
  • A composition of biomarkers for distinguishing subtypes of breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] The composition and relative peak intensities of biomarker combinations used to distinguish Luminal B type breast cancer from HER2 overexpression type are shown in Table 2:

[0078] Table 2 Differential metabolites of Luminal B type vs HER2 overexpression breast cancer

[0079]

[0080] a VIP variable importance projection; b EIC extracts ion current; c HER2 overexpression type relative to Luminal B type breast cancer differential metabolite extraction ion current peak intensity change trend.

Embodiment 2

[0082] The composition and relative peak intensities of the biomarker combinations used to distinguish between Luminal A and Basal-like breast cancers are shown in Table 3:

[0083] Table 3 Differential metabolites of Luminal A type vs Basal-like breast cancer

[0084]

[0085] a VIP variable importance projection; b EIC extracts ion current; c The change trend of ion current peak intensity of differential metabolite extraction between Basal-like type and Luminal A type breast cancer.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Based on the plasma metabolomics research of patients with different molecular subtypes of breast cancer, the present invention finds biomarkers that can be used to distinguish Luminal B type vs HER2 overexpression type, Luminal A type vs Basal-like breast cancer. Compared with the HER2 overexpressing type, the plasma levels of proline, isoleucine, leucine, 2-octenedioic acid and valine in Luminal B patients were significantly up-regulated, and pipecolic acid was significantly down-regulated; Compared with Luminal A type, the content of valine in the plasma of patients with LuminalA type was significantly up-regulated, while pipecolic acid, glycine, glycochenodeoxycholic acid and palmitic acid were significantly down-regulated. The invention can rapidly predict the molecular subtype of breast cancer, and provides an important basis for clinical diagnosis, treatment and prognosis evaluation of breast cancer.

Description

technical field [0001] The present invention relates to the field of tumor biomarkers, in particular to a composition of biomarkers of a group of molecular subtypes of breast cancer. The composition is derived from plasma endogenous small molecule metabolites. Subtype and clinical individualization of treatment are of great importance. Background technique [0002] Breast cancer is the most common malignant tumor in women, with strong heterogeneity, and its morbidity and mortality have been gradually increasing in recent years. Human epidermal growth factor receptor 2 (HER2) is a proto-oncogene in breast cancer patients. Its high level of expression indicates that patients are prone to axillary lymph node metastasis. It is clinically recommended to use corresponding molecular targeted drugs for intervention. The expression of estrogen receptor (ER) is an indispensable and important basis for the application of endocrine drug therapy. According to the gene expression of HER...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N30/02
Inventor 齐炼文李进朱伟范勇
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com